Prognostic value of patient‐reported depression in women with hormone‐responsive early breast cancer in TEXT and SOFT
Cancer · 2025
DOI: 10.1002/cncr.70094 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Cancer, 2025. Verfasst von Karin Ribi und 28 weiteren Autor:innen. Beteiligte Einrichtung: International Breast Cancer Study Group (IBCSG), a division of ETOP (European Thoracic Oncology Platform) IBCSG Partners Foundation, Bern, Switzerlan…. Hauptthemen laut MEDLINE: Breast Neoplasms, Depression. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Pfizer, NCI NIH HHS, European Thoracic Oncology Program and International Breast Cancer Study Group Partners Foundation.
Themen: Depression
Abstract (Originalsprache)
Background
Depression has been identified as an adverse mental health outcome in women with breast cancer (BC). Depression was investigated as a risk factor for poor survival in premenopausal women with hormone‐responsive early BC treated in the TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) trials.
Methods
The data used were from a subset of patients who participated in TEXT or SOFT and completed the Center of Epidemiologic Studies‐Depression scale. Associations between baseline depression‐score categories and baseline characteristics were assessed using the Cochran–Mantel–Haenszel test controlling for antidepressant use. Multivariable proportional hazards regression models were used to test the association between baseline depression and disease‐free survival (DFS) and overall survival (OS). Regression models were adjusted for factors known to be associated with outcomes, baseline antidepressant use, and early treatment cessation.
Results
Forty percent (2287 of 5738) of the women enrolled in the SOFT and TEXT trials were included in this analysis (SOFT, n = 1259; TEXT, n = 1028). Twenty‐seven percent of women reported mild‐to‐moderate or severe depression at baseline. Race ( p = .001), body mass index ( p = .02), family history ( p = .02), and performance status ( p =.007) were significantly associated with the severity of depression. Relative to the no‐symptomatology group, the hazard ratios (overall p = .04) for DFS were 1.34 (95% confidence interval [CI], 1.03–1.76) for women with mild‐to‐moderate depression and 1.34 (95% CI, 0.96–1.87) for those with severe depression. Relative to the no‐symptomatology group, the hazard ratios (overall p = .008) for OS were 1.68 for mild‐to‐moderate depression (95% CI, 1.15–2.44) and 1.67 for those with severe depression (95% CI, 1.05–2.66).
Conclusions
In premenopausal women with hormone‐responsive early BC, depression at baseline is a risk factor for poorer DFS and OFS. Further investigation of the underlying interactive processes is needed.
Trial registration
Clinicaltrials.gov NCT00066703 (SOFT) and NCT00066690 (TEXT).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Breast Cancer Study Group (IBCSG), a division of ETOP (European Thoracic Oncology Platform) IBCSG Partners Foundation, Bern, Switzerland.
- Careum School of Health, Part of the Kalaidos University of Applied Sciences, Zurich, Switzerland.
- Department of Mathematics and Statistics, University of Vermont, Burlington, Vermont, USA.
- The University of Chicago Medical Center, Chicago, Illinois, USA.
- University of Calgary and Canadian Cancer Trials Group, Calgary, Alberta, Canada.
- The Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Karin Ribi, Meredith M Regan
Förderung
- Pfizer
- NCI NIH HHS
- European Thoracic Oncology Program and International Breast Cancer Study Group Partners Foundation
Zitieren
APA
Ribi, K., Cole, B. F., Fleming, G. F., Walley, B. A., Francis, P. A., Abdi, E., Burstein, H. J., Cheng, K. L., Chia, S. K. L., Dakhil, S. R., Davidson, N. E., Della-Fiorentina, S. A., Frith, A. E., Levine, E., Lupichuk, S., Pritchard, K., Salim, M., Stearns, V., Stewart, J., …, & Bernhard, J. (2025). Prognostic value of patient‐reported depression in women with hormone‐responsive early breast cancer in TEXT and SOFT. Cancer. https://doi.org/10.1002/cncr.70094
Vancouver
Ribi K, Cole BF, Fleming GF, Walley BA, Francis PA, Abdi E, et al. Prognostic value of patient‐reported depression in women with hormone‐responsive early breast cancer in TEXT and SOFT. Cancer. 2025. doi:10.1002/cncr.70094
BibTeX
@article{Ribi2025,
author = {Ribi, Karin and Cole, Bernard F and Fleming, Gini F and Walley, Barbara A and Francis, Prudence A and Abdi, Ehtesham and Burstein, Harold J and Cheng, Kit L and Chia, Stephen K L and Dakhil, Shaker R and Davidson, Nancy E and Della-Fiorentina, Stephen A and Frith, Ashley E and Levine, Ellis and Lupichuk, Sasha and Pritchard, Kathleen and Salim, Muhammad and Stearns, Vered and Stewart, Josephine and Valero, Vicente and van der Westhuizen, Andre and Pagani, Olivia and Loi, Sherene and Colleoni, Marco and Gelber, Richard D and Goldhirsch, Aron and Coates, Alan S and Regan, Meredith M and Bernhard, Jürg},
title = {Prognostic value of patient‐reported depression in women with hormone‐responsive early breast cancer in TEXT and SOFT},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70094}
}
EUVIMED